J Viral Hepat. 2018 Jul 15. doi: 10.1111/jvh.12972. [Epub ahead of print]
Long-term Outcome and Recurrence of Hepatitis B Virus following Liver Transplantation from Hepatitis B Surface Antigen-positive Donors in a Chinese Population.
Wei L1,2,3,4, Chen D1,2,3,4, Zhang B1,2,3,4, Zhao Y1,2,3,4, Liu B1,2,3,4, Shi H1,2,3,4, Zeng F1,2,3,4, Ming C1,2,3,4, Jiang J1,2,3,4, Du D1,2,3,4, Chen Z1,2,3,4.
Author information
1
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HuBei, The People's Republic of China.
2
Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, HuBei, The People's Republic of China.
3
NHC Key Laboratory of Organ Transplantation, Wuhan, HuBei, The People's Republic of China.
4
Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, HuBei, The People's Republic of China.
Abstract
Due to the severe shortage of the donor pool in China, a large number of patients are waiting for a suitable liver, or even worse lose the opportunity of transplantation. Reasonable use of hepatitis B surface antigen-positive (HBsAg-positive) donors is one possible strategy to increase the donor pool but the long term outcome in a Chinese population is unknown. To evaluate the safety of using of HBsAg-positive donor for liver transplantation, we set up a multicentric retrospective study from January 1, 2007 to December 31, 2012. A total of 8632 patients underwent liver transplantation during the period and 282 (2.97%) received a liver from a HBsAg-positive donor. 259 cases in both the case and control groups were matched. The incidence of postoperative liver dysfunction, early stage and long term complications and the 1-, 3- and 5-year patient survival (78.92% vs 85.65%, 60.41% vs 69.14%, 58.08% vs 69.14%, respectively) showed no difference between the two groups (P value >0.05). However, the 1-, 3- and 5-year HBV recurrence for patients received the HBsAg-positive donor was higher compared with controls (5.85% vs 1.97%, 11.63% vs 4.46%, 17.94% vs 4.46%, respectively, P value =0.016). Our results showed the use of HBsAg-positive donors is feasible and postoperative antiviral therapy should be managed. This article is protected by copyright. All rights reserved.
KEYWORDS:
anti-HBV therapy; hepatitis B surface antigen-positive donor; liver transplantation